Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Carcinoma in Situ 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Doxylamine × 90 days × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡